Glaxo CEO: new data underscores Avandia safety

(Reuters) - "This is important new information," he said, after
reporting second-quarter results. "Clearly, we stand firmly
behind the safe profile of Avandia. We look forward to this
meeting on Monday and to the ultimate resolution of this
controversy."




Read more at Reuters.com Market News